SpringWorks Therapeutics (NASDAQ:SWTX – Get Rating) announced its quarterly earnings data on Thursday. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.26), Briefing.com reports. The company’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.97) earnings per share.
SpringWorks Therapeutics Price Performance
SWTX stock opened at $36.86 on Friday. The stock has a 50-day moving average price of $26.09 and a two-hundred day moving average price of $42.59. SpringWorks Therapeutics has a 12-month low of $13.60 and a 12-month high of $88.05.
Analyst Ratings Changes
SWTX has been the subject of a number of recent analyst reports. Wedbush set a $53.00 price objective on SpringWorks Therapeutics in a research report on Monday, June 20th. The Goldman Sachs Group lowered their price objective on SpringWorks Therapeutics from $92.00 to $76.00 and set a “buy” rating for the company in a research report on Tuesday, May 24th. Finally, HC Wainwright lowered their price objective on SpringWorks Therapeutics from $142.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, June 6th.
Institutional Investors Weigh In On SpringWorks Therapeutics
SpringWorks Therapeutics Company Profile
SpringWorks Therapeutics, Inc acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.
- Get a free copy of the StockNews.com research report on SpringWorks Therapeutics (SWTX)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.